In recent years, significant progress has been achieved in the characterization of the
transcriptional profiles, gene mutations and structural chromosomal lesions in myeloma …

Multiple myeloma is a clonal disease of long-lived plasma cells and is the second most
common hematological cancer behind Non-Hodgkin's Lymphoma. Malignant transformation …

Multiple myeloma (MM) is a cancerous condition characterized by the proliferation of plasma
cells within the hematopoietic marrow, resulting in multiple osteolytic lesions. MM patients …

Novel therapies that can target the multiple myeloma (MM) cell, the MM cell-patient bone
marrow interaction, and the bone marrow milieu can overcome resistance to conventional …

Cancer-causing mutations disrupt coordinated, precise programs of gene expression that
govern cell growth and differentiation. Microarray-based gene-expression profiling (GEP) is …

Over the past 20 years, the regulatory approval of several novel agents to treat multiple
myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased …

The therapeutic landscape of multiple myeloma (MM) has dramatically changed in the last
15 years with the advent of immunomodulatory drugs and proteasome inhibitors. However …

The knowledge of cancer origin and the subsequent tracking of disease evolution represent
unmet needs that will soon be within clinical reach. This will provide the opportunity to …

The historical lack of preclinical models reflecting the genetic heterogeneity of multiple
myeloma (MM) hampers the advance of therapeutic discoveries. To circumvent this …

Multiple myeloma (MM) is the second‐ranking malignancy in hematological tumors. The
pathogenesis of MM is complex with high heterogeneity, and the development of the …